SCHEDULE 13G/A: PRIMECAP Management Discloses 10.69% Stake in Rhythm Pharmaceuticals

PRIMECAP Management Co./CA/ has reported a 10.69% beneficial ownership stake in Rhythm Pharmaceuticals, Inc. as of December 31, 2024.

Summary

• PRIMECAP Management Co./CA/ reported beneficial ownership of 6,571,190 shares of Rhythm Pharmaceuticals, Inc. common stock.
• This ownership represents 10.69% of the company's outstanding common stock.
• The filing reflects the ownership position as of December 31, 2024, with the Schedule 13G amendment filed on February 13, 2025.
• PRIMECAP Management Co./CA/ is classified as an Investment Adviser.
• PRIMECAP Odyssey Aggressive Growth Fund holds more than five percent of the total outstanding common stock of Rhythm Pharmaceuticals, Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive investment by a reputable asset manager, suggesting confidence in the company's long-term prospects without implying active engagement in management or strategy.

Positives

• A major institutional investor, PRIMECAP Management Co./CA/, holds a substantial 10.69% stake, indicating confidence in Rhythm Pharmaceuticals, Inc.'s long-term prospects.
• The investment is stated to be in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Future Outlook

NA

Management Comments

• PRIMECAP Management Co./CA/ certified that the securities referred to were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing indicates continued institutional investor interest in the biopharmaceutical sector, with a significant stake taken in Rhythm Pharmaceuticals, Inc., a company focused on developing and commercializing therapies for rare genetic diseases of obesity.

Stakeholder Impact

• Shareholders may view this as a positive signal of institutional confidence in the company's value and future prospects.

Key Dates

Keywords

Rhythm Pharmaceuticals, PRIMECAP Management, Schedule 13G, beneficial ownership, institutional investment, common stock, biopharmaceutical, investment adviser